0000000000125338

AUTHOR

Annemieke Cats

showing 2 related works from this author

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

The multidisciplinary management of gastro-oesophageal junction tumours

2016

Abstract Background and scope The management of GOJ cancers remains controversial and may vary between countries. Evidence-based attitudes and guidelines are not easy to elaborate since most of the trials and studies reported mixed cases of oesophageal (both adenocarcinoma and squamous cell tumours), GOJ and gastric cancers. The aim of this expert discussion and position paper is to elaborate practical recommendations that integrate evidence-reported literature and experience-based attitude covering all clinical aspects of GOJ cancer across different specialities and countries in Europe. Methodology Opinion leaders, selected on scientific merit were asked to answer to a prepared set of ques…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologyMultimodal therapyGastro oesophageal junctionPlenary sessionmedicine.diseaseSurgeryClinical expertise03 medical and health sciences0302 clinical medicineMultidisciplinary approach030220 oncology & carcinogenesismedicinePosition paper030211 gastroenterology & hepatologyMedical physicsGastrointestinal cancerbusinessEndoscopic treatmentDigestive and Liver Disease
researchProduct